Patents by Inventor Stefanie Mandl

Stefanie Mandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY
    Publication number: 20240066063
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a modified TGF?RII expression.
    Type: Application
    Filed: May 18, 2023
    Publication date: February 29, 2024
    Applicant: PACT PHARMA, INC.
    Inventors: Charles W. TRAN, John D. Gagnon, Barbara Sennino, Stefanie Mandl-Cashman, Kyle Jacoby, William Lu, Michael Mayne Dubreuil, James S. Byers, III, Michal Mass, Alex Franzusoff
  • METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY
    Publication number: 20240016844
    Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.
    Type: Application
    Filed: June 9, 2023
    Publication date: January 18, 2024
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Bhamini Purandare, Stefanie Mandl-Cashman, Gregg D. Fine, Arati V. Rao, Todd Stallings-Schmitt, Mark Walter Frohlich, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY
    Publication number: 20230355762
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a secondary Payload in an expression construct.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 9, 2023
    Applicant: PACT PHARMA, INC.
    Inventors: Michal Mass, William Lu, Kyle Jacoby, Michael Mayne Dubreuil, Barbara Sennino, Stefanie Mandl-Cashman, James S. Byers, III
  • COMPOSITIONS AND METHODS FOR IDENTIFICATION OF ANTIGEN SPECIFIC T CELLS
    Publication number: 20230194504
    Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Applicant: PACT PHARMA, INC.
    Inventors: Songming Peng, Boi Bryant Quach, Duo An, Xiaoyan Robert Bao, Alex Franzusoff, Barbara Sennino, Olivier Dalmas, Stefanie Mandl-Cashman
  • Compositions and methods for identification of antigen specific T cells
    Patent number: 11513113
    Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: November 29, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Songming Peng, Boi Bryant Quach, Duo An, Xiaoyan Robert Bao, Alex Franzusoff, Barbara Sennino, Olivier Dalmas, Stefanie Mandl-Cashman
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20220193139
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 11304978
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 19, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES
    Publication number: 20220010274
    Abstract: Methods of genetically engineering NeoTCR Products comprising young T cells and methods of manufacturing such cell products.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 13, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Susan Foy, Ines Mende, Stefanie Mandl-Cashman
  • METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY
    Publication number: 20210205363
    Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: July 8, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Bhamini Purandare, Stefanie Mandl-Cashman, Gregg D. Fine, Arati V. Rao, Todd Stallings-Schmitt, Mark Walter Frohlich, Alex Franzusoff
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
    Publication number: 20210205429
    Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 8, 2021
    Applicant: Bavarian Nordic A/S
    Inventors: Susan Foy, Stefanie Mandl, Ryan Rountree, Alain Delcayre
  • METHOD OF TREATING IMMUNOTHERAPY NON-RESPONDERS WITH AN AUTOLOGOUS CELL THERAPY
    Publication number: 20210106621
    Abstract: Methods of treating cancer in Non-Responder Patients with an engineered NeoTCR Product are described herein.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 15, 2021
    Applicant: PACT Pharma, Inc.
    Inventors: Barbara Sennino, Songming Peng, Stefanie Mandl-Cashman, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20210085721
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPY
    Publication number: 20210085720
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a knockout of the expression of the TET2 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR IDENTIFICATION OF ANTIGEN SPECIFIC T CELLS
    Publication number: 20200256849
    Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.
    Type: Application
    Filed: February 12, 2020
    Publication date: August 13, 2020
    Applicant: PACT Pharma, Inc.
    Inventors: Songming Peng, Boi Bryant Quach, Duo An, Xiaoyan Robert Bao, Alexis Franzusoff, Barbara Sennino, Olivier Dalmas, Stefanie Mandl-Cashman
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
    Publication number: 20170266270
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with antagonists or agonists of immune checkpoint inhibitors.
    Type: Application
    Filed: May 8, 2015
    Publication date: September 21, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: SUSAN FOY, STEFANIE MANDL, RYAN ROUNTREE, ALEX FRANZUSOFF
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
    Publication number: 20170106065
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule TIM-3.
    Type: Application
    Filed: May 8, 2015
    Publication date: April 20, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: SUSAN FOY, STEFANIE MANDL, RYAN ROUNTREE
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
    Publication number: 20160271239
    Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 22, 2016
    Applicant: Bavarian Nordic A/S
    Inventors: SUSAN FOY, STEFANIE MANDL, RYAN ROUNTREE, ALAIN DELCAYRE
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20150283220
    Abstract: Provided herein are vaccine compositions having potent adjuvant activity. Such compositions are capable of increasing anti-gen-specific antibody responses and increased frequency of Her-2-specific CD4+ T-cells, have improved anti-tumor efficacy, and are useful in methods of treating cancer.
    Type: Application
    Filed: October 16, 2013
    Publication date: October 8, 2015
    Applicant: Bavarian Nordic, Inc.
    Inventors: Stefanie Mandl, Ryan Rountree, Alain Delcayre
  • Use of MVA to treat prostate cancer
    Patent number: 8377688
    Abstract: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: February 19, 2013
    Assignee: BN ImmunoTherapeutics, Inc.
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl, Ryan Blair Rountree, Fatema Legrand
  • Methods for treating cancer with a recombinant MVA expressing HER-2
    Patent number: 8313740
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: November 20, 2012
    Assignee: BN ImmunoTherapeutics, Inc.
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl